DanCann Pharma A/S has signed an exclusive contract with MYCB1 GmbH for the distribution of full-spectrum extracts based on Bedrocan International varieties
DanCann Pharma A/S (SS: DANCAN) (OTCQB: DCPXF) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, hereby announce that the Company and MYCB1 GmbH (“MYCB1”) has signed an exclusive distribution agreement to introduce MYCB1's portfolio of prescription-only medications based on cannabinoids and the ALETTA 2.0, a Real-World Evidence platform, in the Scandinavian markets, which have a combined population of approximately 21 million people.MYCB1's prescription-only medications are manufactured by MYCB1 GmbH, a German pharmaceutical company based in Steinheim/Westphalia,